Journal of Clinical Oncology
Articles in this Issue
EUnetCCC.
e13617 Background: Cancer is the second leading cause of death in Europe and the primary cause of mortality among individu...
Extended monitoring and biomarker analysis in metastatic melanoma patients treated with TIL therapy and conditioning-replacing igrelimogene litadenorepvec virotherapy: Pre-infusion immune cell and cytokine profiles associated with survival.
2538 Background: Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can be effective in metastatic melanoma, but i...
Real-world adoption and pathological insights of neoadjuvant chemoimmunotherapy in resectable NSCLC: Single-institution experiences and perspectives.
e20077 Background: Since March 2022, neoadjuvant or perioperative PD-(L)1 inhibitor plus platinum-based chemotherapy has b...
Shared treatment decision-making between physicians and their patients with metastatic urothelial carcinoma: Results of a real-world survey in Europe and the United States.
e16581 Background: Metastatic urothelial carcinoma (mUC) is associated with poor prognosis, but recent treatment (tx) appr...
Clinical genomic and quantitative IHC–driven target identification to enable precision, tumor-selective activation of SynchroLINK T2X antibody-drug conjugates.
e15043 Background: Conventional antibody–drug conjugates (ADCs) rely on single-step payload release and are often limited...
Clinical characteristics, molecular features, and treatment of primary central nervous system melanoma.
9523 Background: Primary Central Nervous System (CNS) Melanoma is a rare and aggressive malignancy, comprising 1% of melan...
Brain metastases in upper gastrointestinal tumours: A multi-centre, retrospective analysis of clinical predictors and outcomes in a multi-ethnic Asian cohort.
e16079 Background: Gastric and esophageal cancers are the 5th and 11th most common worldwide, but brain metastasis (BM) in...
NRG1 fusions in non–small cell lung cancer (NSCLC): Prevalence, clinical and molecular features from a real-world cohort profiled with DNA plus RNA-based sequencing.
e15111 Background: NRG1 gene fusions are rare oncogenic drivers in non-squamous NSCLC, occurring in approximately 0.2–0.3%...
The efficacy of trastuzumab deruxtecan after HER2-TKI exposure in HER2 exon 20 insertion–positive non–small cell lung cancer: Results from a large-scale nationwide genomic screening (LC-SCRUM-Asia).
8531 Background: Although reduced efficacy of HER2-TKIs after trastuzumab deruxtecan (T-DXd) has been reported in HER2 exo...
ASC4Kids-2: Asciminib in pediatric chronic myeloid leukemia with or without T315I.
TPS6606 Background: Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs), including imatinib, dasati...
Trends in infection-related mortality among older adults with multiple myeloma in the United States over the last two decades.
e19553 Background: Multiple myeloma (MM) is associated with profound immune dysfunction and treatment-related immunosuppre...
Comparison of survival outcomes in <i>ALK</i> fusion–positive advanced non–small cell lung cancer patients diagnosed by next-generation sequencing or RT-PCR: A propensity score–weighted analysis.
e20669 Background: Although ALK inhibitors significantly improve the prognosis of...
A retrospective analysis of cardiovascular outcomes in patients with prostate cancer treated with upfront gonadotropin-releasing agonist versus antagonists utilizing real-world data.
e17101 Background: Prostate cancer is commonly treated with androgen deprivation therapy (ADT). This is achieved using gon...
Baseline autoantibodies and treatment outcomes in metastatic melanoma treated with anti–PD-1 or ipilimumab combination immunotherapy.
e21505 Background: B cells can exert both pro- and anti-tumor effects depending on the cancer type, disease stage, and the...
Emotional burnout among oncology clinicians in Russia: Results of a national cross-sectional survey.
9014 Background: International reports suggest a high prevalence of burnout in oncology, but contemporary Russian data are...
An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors.
3011 Background: SKB500 is an antibody drug conjugate (ADC) composed of an antibody targeting the B7 homolog 3 (B7-H3), wh...
Progression patterns and management after frontline platinum in advanced epithelial ovarian cancer (EOC).
e17581 Background: Most patients with EOC relapse after frontline platinum-based chemotherapy, even with maintenance thera...
Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.
625 Background: I-SPY 2 is a multicenter phase II adaptive platform trial evaluating novel agents for stage II-III high-ri...
Utilization of germline genetic testing in prostate, pancreatic, and ovarian cancer in a rural setting.
e22634 Background: Prostate, pancreatic, and ovarian cancer are malignancies with known high prevalences of pathogenic ger...
CTNow pilot study: A multilevel clinical trial education and clinical trial referral coordination intervention for rural oncology providers and patients with cancer.
TPS1676 Background: Enhancing patient access to cancer clinical trials is an ASCO and NCI priority. Major barriers to clin...
A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non–small cell lung cancer (NSCLC).
8574 Background: HB0025, developed by Huaota, is a novel anti-PD-L1/VEGF bispecific antibody with VEGFR1D2 linked at the N...
A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
9518 Background: Advanced melanoma has a high mortality rate; however, survival for patients (pts) treated with anti–PD-1–...
Synergistic efficacy of intrathecal PD-1 blockade combined with whole-brain radiotherapy for melanoma leptomeningeal metastases: A real-world analysis.
e14023 Background: Leptomeningeal metastasis (LM) from malignant melanoma remains a catastrophic event with a historical m...
Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm): A multicenter retrospective study.
4144 Background: Huge hepatocellular carcinoma ((huge HCC, ≥ 10 cm)) has poor prognosis with limited systemic therapy effi...
Phase I study of IMM2510, a PD-L1/ VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC.
8580 Background: Despite advancements in first-line treatments such as immunotherapy and targeted therapies, resistance to...